ArticleJournal of robotic surgery2026
Evaluation of mitoxantrone hydrochloride injection versus carbon nanoparticle suspension in robotic thyroidectomy for papillary thyroid carcinoma.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate whether mitoxantrone hydrochloride injection (MHI) provides lymph node tracing and parathyroid preservation outcomes comparable to those of carbon nanoparticle suspension injection (CNP) during robotic thyroidectomy for papillary thyroid carcinoma (PTC). We conducted a retrospective review of 507 patients with PTC who underwent robotic thyroidectomy from September 2024 to September 2025. Patients were categorized into CNP and MHI groups based on the tracer utilized. After 1:1 propensity score matching, 62 matched pairs were selected for the final analysis. The primary outcomes encompassed the counts of dissected, metastatic, and stained lymph nodes, along with outcomes related to parathyroid preservation. Secondary outcomes included perioperative parameters and postoperative complications. After matching, the baseline characteristics of the two groups were well balanced. There were no notable differences in the counts of total lymph nodes, metastatic lymph nodes, stained level VI lymph nodes, parathyroid autotransplantation, incidental parathyroid resection, or intraoperative parathyroid identification. Preoperative, postoperative day 1, and 6-month postoperative serum calcium and parathyroid hormone (PTH) levels were comparable between the groups. Surgical recovery indicators and postoperative complication rates were also similar between the groups. In this single-center, propensity score-matched retrospective study, MHI showed efficacy and safety similar to those of CNP in lymph node tracing and parathyroid preservation. These findings suggest that MHI may be a practical alternative tracer in robotic thyroid cancer surgery.
Indexed as
Identifiers
42474863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.